Mucoadhesive Particles: A Novel, Prolonged-Release Nanocarrier of Sitagliptin for the Treatment of Diabetics
المؤلفون المشاركون
Venugopala, K. N.
Attimarad, Mahesh V.
SreeHarsha, Nagaraja
Hiremath, Jagadeesh G.
Al-Dhubiab, Bandar E.
Ramnarayanan, Chandramouli
Nair, Anroop B.
Satish, Roopashree T.
Shariff, Arshia
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-11-03
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Sitagliptin (MK–0431) is a widely and commonly used oral hypoglycemic drug in the treatment of type 2 diabetes mellitus; patients typically take higher doses of this drug (50 mg, twice daily).
One drawback is that only 38% of the drug is bound reversibly to plasma proteins and 79% is excreted in urine without being metabolized.
To overcome this issue, there is a need for a better drug-delivery method to improve its efficacy in patients.
It has been found that in existing formulations, the drug content is 72.5% ± 5% and the percentage yield is 84.9% ± 3%.
In this study, sitagliptin nanoparticles (sizes ranging from 210 to 618 nm) were developed.
The bioadhesion properties of the nanoparticles, as well as the swelling of the nanoparticles on the mucus membrane aided in sustained drug release.
The pattern of drug release was in accordance with the Peppas model.
Fourier-transform infrared (FTIR) spectroscopy demonstrated that there were no significant interactions between sitagliptin and chitosan.
Differential scanning calorimetry (DSC) results showed an absence of drug peaks due to the fact that the drug was present in an amorphous state.
Mucoadhesive nanoparticles were formulated using sitagliptin and were effective for about 12 hours in the gastrointestinal tract.
When compared to conventional sitagliptin administration, use of a nanoparticle delivery system demonstrated greater benefits for use in oral delivery applications.
This is the first time that a drug-delivery method based on the mucoadhesive properties of nanoparticles could prolong the drug-release time of sitagliptin.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
SreeHarsha, Nagaraja& Ramnarayanan, Chandramouli& Al-Dhubiab, Bandar E.& Nair, Anroop B.& Hiremath, Jagadeesh G.& Venugopala, K. N.…[et al.]. 2019. Mucoadhesive Particles: A Novel, Prolonged-Release Nanocarrier of Sitagliptin for the Treatment of Diabetics. BioMed Research International،Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1125008
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
SreeHarsha, Nagaraja…[et al.]. Mucoadhesive Particles: A Novel, Prolonged-Release Nanocarrier of Sitagliptin for the Treatment of Diabetics. BioMed Research International No. 2019 (2019), pp.1-9.
https://search.emarefa.net/detail/BIM-1125008
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
SreeHarsha, Nagaraja& Ramnarayanan, Chandramouli& Al-Dhubiab, Bandar E.& Nair, Anroop B.& Hiremath, Jagadeesh G.& Venugopala, K. N.…[et al.]. Mucoadhesive Particles: A Novel, Prolonged-Release Nanocarrier of Sitagliptin for the Treatment of Diabetics. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1125008
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1125008
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر